Patritumab deruxtecan HER3-DXd HER3 NSCLC

Indicated For

EGFR-mutated non-small cell lung cancer, NSCLC

About This Medication

# Daiichi Sankyo Patient Assistance for Patritumab Deruxtecan: How to Get Your Medication ## About This Guide Patritumab deruxtecan (HER3-DXd) is an investigational HER3-directed antibody drug conjugate being jointly developed by Daiichi Sankyo and Merck for patients with certain types of non-small cell lung cancer. If you have been prescribed this medication and are concerned about cost, Daiichi Sankyo offers patient assistance programs to help eligible patients access their medications at reduced or no cost. ## About Patritumab Deruxtecan Patritumab deruxtecan is a specifically engineered HER3-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo using their proprietary DXd technology. The medication consists of a fully human anti-HER3 monoclonal antibody attached to topoisomerase I inhibitor payloads via cleavable linkers. This investigational medicine is being studied for patients with previously treated locally advanced or metastatic EGFR-mutated non-small cell lung cancer. ## Who Qualifies for Assistance Daiichi Sankyo's patient assistance programs are designed to help patients who: - Have been prescribed patritumab deruxtecan by their treating physician - Are uninsured or underinsured - Are unable to identify alternative payment sources - Are experiencing financial difficulty affording their medication - Have Medicare or other insurance coverage but still face significant out-of-pocket costs Patients with commercial insurance may also qualify for additional support programs that help reduce out-of-pocket expenses. ## Income Eligibility While specific income thresholds for patritumab deruxtecan assistance are not publicly detailed in current program materials, Daiichi Sankyo's patient assistance programs generally consider household income when determining eligibility. The company works with patients on a case-by-case basis to assess financial need. There are typically no strict income cutoffs that automatically disqualify patients—instead, programs evaluate your individual financial circumstances. If you are unsure whether you qualify based on your income, contact Daiichi Sankyo's patient assistance team directly. They can discuss your specific situation confidentially. ## Insurance Requirements You may be eligible for patient assistance if you are: - **Uninsured**: You have no health insurance coverage - **Underinsured**: You have insurance but face high out-of-pocket costs, high deductibles, or your insurance does not cover patritumab deruxtecan - **Medicare patients**: You may qualify for assistance with copayments, coinsurance, or deductibles - **Commercially insured**: You may qualify for programs that help reduce your out-of-pocket costs If your insurance denies coverage or you have questions about your coverage, Daiichi Sankyo's patient assistance team can help you understand your options and may be able to provide your first dose at no cost while coverage decisions are being made. ## How to Apply ### Step 1: Contact Daiichi Sankyo AccessCentral4U Reach out to Daiichi Sankyo's patient assistance program: **Phone**: 1-866-4-DSI-NOW (1-866-437-4669) **Hours**: Monday – Friday, 8:00 AM – 6:00 PM ET (excluding holidays) **Website**: www.DSAccessCentral4U.com You can also visit the Daiichi Sankyo Medical Access Program website at daiichisankyo-map.com for information about investigational medicine access programs. ### Step 2: Provide Required Information When you contact the program, be prepared to provide: - Your prescription for patritumab deruxtecan from your treating physician - Proof of income (recent tax returns, pay stubs, or benefit statements) - Proof of citizenship or residency - Insurance information (if applicable) - Information about your financial situation and any hardship factors ### Step 3: Complete the Application Daiichi Sankyo's patient assistance team will guide you through the application process. You can apply by phone, mail, or online through their website. The team can answer questions and help you gather necessary documentation. ### Step 4: Receive Your Medication Once your application is approved, Daiichi Sankyo will arrange for your medication to be provided according to the program terms. If there is a delay in your insurance coverage decision, the program may provide your first dose at no cost. ## Timeline and Delivery While specific processing times for patritumab deruxtecan assistance are not publicly detailed, Daiichi Sankyo works to process applications as quickly as possible. The exact timeline depends on: - How quickly you submit your application and required documents - Whether additional information is needed to verify eligibility - Your insurance company's coverage decision timeline (if applicable) Once approved, your medication will be delivered according to your treatment schedule and local regulations. Your treating physician and healthcare team will coordinate with Daiichi Sankyo to ensure timely delivery. ## What If Your Application Is Denied If your application for patient assistance is denied, you have several options: 1. **Ask why**: Contact Daiichi Sankyo to understand the specific reason for denial. You may be able to provide additional information or clarification. 2. **Appeal**: Many programs allow you to appeal a denial decision with additional documentation or updated financial information. 3. **Explore alternatives**: Ask your healthcare team about other assistance programs, clinical trials, or payment plans. 4. **Contact Partnership for Prescription Assistance (PPA)**: Daiichi Sankyo participates in the PPA program (www.pparx.org), a national coalition that helps patients identify and access multiple assistance programs. ## Reauthorization and Refills If you are approved for patient assistance, ask Daiichi Sankyo about: - How long your assistance will continue - Whether you need to reapply or reauthorize your assistance - How to request refills of your medication - What happens if your financial situation changes Your patient assistance coordinator can explain the specific terms of your program and help you understand any renewal requirements. ## Additional Resources **Partnership for Prescription Assistance (PPA)**: Visit www.pparx.org to learn about other assistance programs you may qualify for. The PPA helps patients identify potential assistance programs, assess eligibility, and obtain enrollment forms. **Your Healthcare Team**: Your doctor, nurse, social worker, or pharmacist can provide additional support and may have resources or recommendations for patient assistance programs. ## Important Disclaimer This guide provides general information about Daiichi Sankyo's patient assistance programs for patritumab deruxtecan. Program details, eligibility requirements, and benefits may change. For the most current and accurate information, contact Daiichi Sankyo AccessCentral4U directly at 1-866-437-4669 or visit www.DSAccessCentral4U.com. Patritumab deruxtecan is an investigational medicine. Safety and efficacy have not been established for all indications. Always follow your treating physician's guidance regarding your treatment. This information is not a substitute for professional medical advice. Consult with your healthcare provider about whether patritumab deruxtecan is appropriate for your condition and about any questions regarding your treatment or medication assistance.

Program information last verified: March 30, 2026